Comparing the current results to its competitors, Zeo Scientifix Inc reported Revenue increase in the 2 quarter 2026 by 124.63 % year on year, while most of its competitors have experienced contraction in revenues by -80.64 %, achieved in the same quarter.
Zeo Scientifix Inc 's Comment on Competition and Industry Peers
The company operates within the regenerative medicine and RAAM product sectors, which are regulated by FDA rules effective May 2021. Competitors in this market are required to conduct research and development, submit Investigational New Drug (IND) applications, and obtain biologic licenses to comply with these regulations. The market includes autologous solutions derived from blood, bone marrow, and adipose tissue, representing the fastest-growing segment due to favorable regulatory conditions. Additionally, many competitors offer products intended for aesthetic or topical use, which face fewer regulatory restrictions. Allogenic competitors primarily function as producer-distributor companies. The company seeks to differentiate itself through clinical trials, FDA biologics licensing, and enhanced education and support. Demand for RAAM products is high and projected to increase due to demographic and healthcare trends.
Competitors identified in company filings include Benev Company Inc., DermaSciences, Direct Biologics, Exocel Bio, Frontier Biologics, Invitrx Therapeutics, Kimera Labs, MiMedix Group, Inc., Neobiosis, Platinum Biologics, Re-gen Active Lab, Regenexx, Signature Biologics, and Vitti Labs LLC.
Aura Biosciences Inc is a biotechnology company that focuses on developing and commercializing therapies to treat cancer. They utilize their proprietary Tumor Paint technology to selectively deliver light-activated drugs directly to tumors, aiming to improve treatment outcomes and minimize side effects.
Mesoblast Ltd is a biotechnology company that operates on a business model focused on the development and commercialization of proprietary cell-based regenerative medicines. They aim to transform the treatment of various degenerative diseases by utilizing their patented technology and strategic partnerships with pharmaceutical companies.
Humacyte Inc is a biotechnology company that focuses on creating bioengineered human tissue constructs for numerous medical applications. Their business model revolves around developing and commercializing their proprietary Humacyl platform, which uses a patient's own cells to create acellular scaffolds that mimic human tissue. These tissue constructs can be used for various purposes such as vascular replacements, functional tissues, and potential regenerative medicine therapies.
Brainstorm Cell Therapeutics Inc's business model is centered around developing and commercializing innovative adult stem cell therapies for neurodegenerative diseases.
Sources:
Zeo Scientifix Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Zeo Scientifix Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
